Targeting of CAFs might also have additional beneficial therapeutic effects because these cells not only secrete tumor sustaining ECM proteins like collagens, fibronectin, vitronectin, or laminins, or glycosaminoglycans and proteoglycans, for example, hyaluronan, but also synthesize tumor growth- and resistance-promoting growth factors as well as cytokines and chemokines suppressing the tumor immune response [78]. The gene discussed is FN1; the disease is neoplasm.